Breaks Categories: News

WednesdayMar 02, 2022 11:27 am

CannabisNewsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Vessel Enters Distribution Agreement with JustCBD Partner

Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has inked a distribution deal with Florida-based Speedy Distribution. Speedy is a core partner of JustCBD, which was just acquired by Flora Growth in a transaction announced earlier this week. The announcement noted that its consumer technology brand, Vessel, will launch in Speedy’s cash-and-carry distribution center and will include a select offering from FLGC’s product portfolio; the products will expand into traditional smokeshop channels. JustCBD has more than 300 products and some 300,000 customers, with a network of more than 14,000 stores across the…

Continue Reading

ThursdayFeb 17, 2022 11:41 am

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Partners with University of Milan to Test, Evaluate New Line of Smart-Patch Wellness Products

RYAH Group (CSE: RYAH), a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry, will be collaborating with the University of Milan, Italy, on a new wellness line of topical patches. The partnership will be testing the permeation and effectiveness of the patches, which RYAH developed for its Smart Patch system. University scientists are focused on determining the permeation effectiveness of vitamin and nutraceutical patches as an alternative slow-release, nondigested solution to consumer intake; they will also use the RYAH Smart Patch “boost capability” to monitor and…

Continue Reading

WednesdayFeb 16, 2022 1:49 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Evolution to Commercial Sales to Health and Wellness Market Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. According to the piece, InMed achieved Q222 financial results that reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3 million, all cannabichromene (“CBC”). “As of January, it also began selling cannabicitran (‘CBT’) to the health and wellness market,” notes the report. “The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids and rounds…

Continue Reading

TuesdayFeb 15, 2022 12:36 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names BayMedica VP of Sales, Releases Q2 2022 Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has appointed Gerard (Jerry) P. Griffin III as vice president of sales and marketing at BayMedica, a wholly owned subsidiary of InMed. In his new role, Griffin will manage the commercialization of BayMedica’s health and wellness business including existing products as well as the launch of new products. Griffin brings a rich background to this position, having a proven track record as a veteran sales executive. He has served in several senior positions in Fortune 500 companies, including most recently as VP of sales…

Continue Reading

ThursdayFeb 10, 2022 12:20 pm

CannabisNewsBreaks – RYAH Group Inc. (CSE: RYAH) Receives Notice of Allowance by USPTO for Smart Medical Inhaler System

RYAH Group (CSE: RYAH) today announced that the U.S. Patent and Trademark Office (the “USPTO”) has issued a Notice of Allowance for U.S. patent application number 15/924,172, filed in respect of the company's IoT-powered, Smart Medical Inhaler system by its wholly owned subsidiary, Potbotics Inc. The hybrid conduction and convection RYAH Smart Medical Inhaler was recently granted Medical Device Certification under ISO 13485:2016/MDSAP and EN ISO 13485:2016 standards for both its hardware and software. “Receiving this Notice of Allowance by the USPTO on our Smart Medical Inhaler is the result of dedication and great effort by all of our product…

Continue Reading

TuesdayFeb 08, 2022 2:59 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Reaches ‘Major Milestone,’ Closes on Acquisition

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, through its wholly owned subsidiary RWB Michigan LLC, has closed on the acquisition of PharmaCo Inc. The acquisition, which was originally announced in 2020, brings an extensive list of assets to RWBYF, including 21 medical and adult-use cannabis licenses, eight fully operating dispensaries with five dually licensed, two operational indoor cultivation facilities totaling more than 30,000 square feet, one municipally licensed 10-acre outdoor cultivation facility ready for the 2022 season, two ready-to-open dispensaries, and22 owned properties for potential additional cultivation and dispensary locations.…

Continue Reading

WednesdayFeb 02, 2022 2:20 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Significant Findings from Sildenafil Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. The study was designed to evaluate LEXX’s proprietary DehydraTECH(TM) processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil for potential use in the management of erectile dysfunction. According to the company, the DehydraTECHsildenafil delivered 74% more drug at four minutes than the concentration-matched, generic control formulation with faster and higher overall delivery of sildenafil into the bloodstream evidenced over the course of the study. The most recognizable sildenafil product available currently is Viagra(R), but some users find it slow to act. Lexaria hopes…

Continue Reading

WednesdayFeb 02, 2022 12:36 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Seeks Approval to Study Patent-Pending Cannabinoid-Based Product to Treat COVID-19

Flora Growth’s (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is hoping to begin research on its patent-pending, cannabinoid-based product. The company is requesting approval from INVIMA, the Colombian FDA, noting that recent studies indicate the potential for cannabinoids to display viral inhibition. FLGC’s research division, Flora Pharma, has filed a USPTO provisional patent application regarding the company’s cannabinoid-based formula, and the company is hoping to take the product through clinical trials under an emergency use authorization (“EUA”) from INVIMA.According to the company, the intent of the study is to identify safe and efficacious…

Continue Reading

FridayJan 28, 2022 11:11 am

CannabisNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Announces Closing of Embark Acquisition

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an innovative health and wellness beverages and products company, has closed on its acquisition of Embark Health Inc., solventless cannabis extraction and delivery technology provider. According to the company, the acquisition will be a significant driver of growth for BevCanna, accelerating its already strong upward trajectory. Embark owns a unique range of brands across all three cannabis 2.0 categories, meaning that BevCanna will now be able to sell differentiated and complementary adult-use and wellness products. In addition, Embark brings a British-Columbia-based, state-of-the-art production facility with $17 million  in tangible and intangible assets to…

Continue Reading

ThursdayJan 27, 2022 12:32 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Annual Letter from CEO, Stakeholder Update

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today provided an annual letter from CEO Chris Bunka and a thorough strategic update to all stakeholders. In the update, Bunka described Lexaria’s key area of focus to improve the company’s understanding of the capabilities of its ground-breaking DehydraTECH(TM) drug-delivery technology to enhance its abilities to commercialize and profit from this technology platform. “DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform,” Bunka explains in the letter. “Expecting entire industries to change overnight to adopt a revolutionary new process is…

Continue Reading